SCOTTSDALE, Ariz., Feb. 22, 2010 (GLOBE NEWSWIRE) -- Health Enhancement Products, Inc. (OTCBB:HEPI) has filed a provisional patent application to protect biologically active molecules isolated from its ProAlgaZyme algae infusion. These previously undiscovered molecules have been mapped against available databases and are known to be responsible for the dramatic cholesterol regulation effects published in the summer of 2009, whereby LDL cholesterol levels were lowered and HDL cholesterol levels raised in a hamster study conducted at Wayne State University's department of Nutrition and Food Science, under the direction of Dr. Smiti Gupta.
The Company has previously marketed ProAlgaZyme (PAZ) as a standalone product, and now intends to develop a variety of derivatives for a broader range of applications. HEPI recently retained the services of Kohn & Associates, Inc., the noted biotech patent law firm, to begin a comprehensive program of new patent filings as a result of the research work conducted over the past several months.
The Company anticipates filing additional patents as soon as practical, at which time the Company will have the ability to legally disclose the identification of the cholesterol mechanisms and describe the isolated compounds affecting these mechanisms.
In addition, the Company announced that its research efforts had recently expanded to include faculty and independent researchers associated with SUNY- Buffalo, Vanderbilt University and Bruker Analytical Services, among others, as various experts probed cholesterol metabolism, molecular structure and genetic mechanisms at the cellular level.
"The nature of biological research can be both frustrating and exhilarating, I am thrilled to say today HEPI reached an important milestone in its history," stated John Gorman, director of sales and a board member. "Years of research and analysis of the proper mechanisms of PAZ have led us to today's developments. Today's announcement has now allowed us to pursue numerous opportunities we were not able to follow before we filed these patents. We look forward to updating the investment community as we are able to announce further developments on monetizing our valuable asset."
About Health Enhancement Products, Inc.
Health Enhancement Products, Inc. (OTCBB:HEPI) is a health & wellness company engaged in the development of products comprised of pure, all-natural compounds that can be used as a dietary supplement and food additive. The Company's product is ProAlgaZyme® (PAZ™), a liquid product drawn from living algae grown in purified water. The water in which the algae are grown is drawn off, filtered and bottled under the trademark ProAlgaZyme®.
Safe Harbor Statement
Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, and the company's ability to secure funding. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and those actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.
For more information, please visit www.heponline.com/" target="_top" rel="nofollow">http://www.heponline.com.